When is Mounjaro typically denied?
Mounjaro is Eli Lilly's tirzepatide formulation indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. Insurance denials are common — particularly for plans that restrict GLP-1s to specific diagnoses or require step therapy. Knowing the exact denial reason on your Explanation of Benefits (EOB) is the first step toward a successful appeal.
Common denial reasons & how to counter them
Prescribed off-label for weight loss
Without a T2D diagnosis, Mounjaro is rarely approved. Request a switch to Zepbound (same molecule, on-label for obesity and OSA).
Step therapy required
Document trials of metformin and any preferred GLP-1 (often Ozempic or Trulicity) — dose, duration, A1c response, side effects, or contraindications.
A1c below plan threshold
Submit the most recent A1c. If below the threshold, document cardiovascular risk per ADA — GLP-1/GIP agents are recommended independent of A1c in patients with ASCVD, CKD, or HF.
Non-formulary status
Request a formulary exception with documentation that preferred alternatives have failed, are contraindicated, or are expected to be less effective.
Documentation checklist
Strong appeals are built on documentation. Ask your prescriber's office to include each of the following in the appeal packet:
- T2D diagnosis with ICD-10 code (E11.x)
- Most recent A1c and trend over past 6–12 months
- Documented trials of metformin and any preferred GLP-1 (dose, duration, outcome)
- Cardiovascular, renal, or heart-failure comorbidities if applicable
- Current diabetes medication list
- Letter of medical necessity from the prescriber
- Copy of the original denial letter / EOB
Sample appeal letter for Mounjaro
Copy the letter below into your appeal and have your prescriber personalize the clinical details. Always attach supporting chart notes and lab results.
[Date] [Insurance Plan Name] Attn: Appeals Department [Address] Re: Appeal of Denial — Mounjaro (tirzepatide) Member: [Patient Name] Member ID: [ID] Claim/Reference #: [from denial letter] To the Appeals Reviewer: I am writing to appeal the denial of Mounjaro (tirzepatide) issued on [denial date]. The stated reason was: "[exact reason from EOB]." [Patient] is a [age]-year-old [sex] with type 2 diabetes (ICD-10: E11.9), most recent A1c of [value] on [date] despite [current therapies — e.g., metformin 2000 mg, prior sulfonylurea, prior GLP-1]. [Patient] also has [relevant comorbidities — established ASCVD, CKD, HF, obesity (BMI [value])]. Mounjaro is FDA-approved as adjunct to diet and exercise to improve glycemic control in adults with T2D. The ADA Standards of Care recommend a GLP-1/GIP receptor agonist for patients with T2D and high cardiovascular risk, ASCVD, CKD, or HF — independent of A1c — and as a preferred agent when weight management is also a treatment goal. Tirzepatide's dual GIP/GLP-1 mechanism has demonstrated superior A1c and weight reduction in head-to-head trials (SURPASS-2) versus semaglutide 1 mg. [Patient] requires this efficacy given [clinical rationale]. Enclosed: chart notes, A1c trend, prior medication history, letter of medical necessity, and the original denial. I respectfully request that this denial be overturned. Sincerely, [Prescriber Name, Credentials] [Practice / NPI]
FAQ
Get a Mounjaro approval-likelihood score
Answer a few clinical questions and receive a personalized assessment of your approval odds, plus a prior-authorization checklist tailored to your plan.
Educational guidance only — not medical or legal advice.